MYGN Earnings Prediction
The chart below shows how MYGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MYGN sees a -0.02% change in stock price 10 days leading up to the earnings, and a +1.45% change 10 days following the report. On the earnings day itself, the stock moves by -1.71%. This data can give you a slight idea of what to expect for the next quarter's release.
MYGN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
210.60M
7.12%
-1.27%
Gross Margin
71.65%
4.34%
2.02%
Operating Margin
-8.21%
-28.92%
-1.68%
Net Margin
-20.18%
27.16%
94.79%
EPS
-0.47
-30.56%
95.83%
No Data Available
MYGN Earnings Analysis
Myriad Genetics Inc Corporation (MYGN.O) Earnings Conference Call
Positive
Strong Revenue Performance: Myriad Genetics achieved 11% revenue growth in 2024 compared to 2023, indicating strong performance across its portfolio.
Financial Performance Highlights: The company generated approximately $589 million in adjusted gross profits and $40 million in adjusted EBITDA, showcasing financial health and profitability.
Positive Adjusted EPS: Myriad maintained a positive adjusted EPS of $0.14, reflecting effective cost management and revenue generation strategies.
Strong Liquidity Position: The company has approximately $158 million in liquidity, providing a solid financial foundation for future growth and investments.
AI Integration in Oncology: Myriad's partnership with PATHOMIQ to integrate advanced AI technology into its oncology products is expected to enhance testing solutions and improve patient outcomes.
High Net Promoter Score: The company reported a strong Net Promoter Score of 72, indicating high satisfaction among providers and payers, which supports its reputation in the market.
Women’s Health Revenue Growth: Myriad's women’s health team delivered 14% revenue growth year-over-year, demonstrating successful market penetration and product acceptance.
GeneSight Revenue Surge: GeneSight, Myriad's pharmacogenomics product, saw a 23% revenue growth year-over-year, highlighting strong demand despite reimbursement challenges.
Oncology Revenue Growth: The oncology segment, particularly MyRisk, experienced a 24% revenue growth year-over-year, reflecting the effectiveness of its product offerings in the market.
Negative
Volume Growth Challenges: Slower-than-expected volume growth in Q4, particularly in the unaffected hereditary business due to the focus on the launch of Prequel and EMR workflow conversions taking longer than anticipated.
Health System Integration Delays: Workflow disruptions at certain health systems have taken longer to fully integrate, which may delay increased volumes and affect overall performance.
Divestiture Impact on Revenue: The divestiture of the EndoPredict business in Europe removed approximately $11 million of annual run rate revenue, impacting overall revenue growth.
Reimbursement Challenges Impacting Growth: Despite strong demand for GeneSight, there are ongoing reimbursement challenges with UnitedHealthcare not covering this category of test for their patients, which could hinder future growth.
Q1 Adjusted EPS Loss: The company anticipates a first quarter adjusted EPS loss of between $0.04 and $0.08, indicating potential short-term financial challenges.
MYGN FAQs
How does MYGN typically perform around its earnings report dates?
Is Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
MYGN Earning Call Sentiment
Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2024 Earnings Call Transcript
MYGN.O
3.81%Positive
The company reported strong financial performance with 11% revenue growth, improved gross margins, and positive adjusted EPS. Despite increased R&D expenses, guidance remains positive, with plans for product launches and market expansion. The Q&A section highlighted strategic investments and opportunities for market share gains, although some management responses were vague. The lack of a share buyback or dividend program is a minor drawback, but overall, the positive financial metrics and growth prospects suggest a positive stock price movement.
